Presidio Pharmaceuticals, Inc. and Numerate Conclude Research Collaboration; New Lead Compounds Targeting Hepatitis C Virus Discovered
SAN FRANCISCO & SAN BRUNO, Calif.--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc., and Numerate, Inc., today announced that they have concluded their two-year collaboration to discover new compounds that target hepatitis C virus (HCV).